MedPath

The prospective trial to validate the superior efficacy of sequential therapy to standard therapy in Helicobacter pylori eradicatio

Not Applicable
Completed
Conditions
Diseases of the digestive system
Registration Number
KCT0000014
Lead Sponsor
Daegu-Kyungpook Gastrointestinal Study Group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
348
Inclusion Criteria

1) Ages between 18 and 85
2) Peptic ulcer(active or inactive) in endoscopy and positive for rapid urease test
3) No peptic ulcer in endoscopy but positive for rapid urease test, who want to eradicate the H.pylori
4) Participants who agree to participate in this study after informed consent

Exclusion Criteria

1) Patients who refused to participate in this study
2) Paticipants with a history of treatment for H.pylori
3) Use of proton pump inhibitor, antibiotics, H2-receptor antagonists, or bismuth in the previous 2 weeks
4) Concomitant use of anticoagulants, aspirin or steroids
5) History of gastric resection including endoscopic mucosal resection
6) Combined severe cardiovascular, pulmonary or endocrine disorders
7) Serious hepatic or renal dysfunction
8) hematologic disorders
9) Any kinds of malignant diseases
10) pregnancy or lactation, women who were not willing to practice acceptable contraception

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath